BEAM
Beam Therapeutics Inc

6,404
Mkt Cap
$2.73B
Volume
1.5M
52W High
$36.44
52W Low
$13.53
PE Ratio
-6.08
BEAM Fundamentals
Price
$25.99
Prev Close
$26.95
Open
$26.97
50D MA
$28.32
Beta
1.89
Avg. Volume
2.16M
EPS (Annual)
-$4.58
P/B
2.83
Rev/Employee
$131,507.25
$1,352.05
Loading...
Loading...
News
all
press releases
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to Sell
Wall Street Zen downgraded Beam Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. $BEAM
IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 96.4% during the 3rd quarter, according to its most recent disclosure with the...
MarketBeat·5d ago
News Placeholder
Cathie Wood buys $1.9 million of megacap tech stock
Cathie Wood, CEO of Ark Investment Management, typically focuses on small- and mid-cap technology stocks, but she occasionally ventures into megacap growth stocks. This approach can help add...
TheStreet.com·10d ago
News Placeholder
Y Intercept Hong Kong Ltd Takes Position in Beam Therapeutics Inc. $BEAM
Y Intercept Hong Kong Ltd bought a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm...
MarketBeat·10d ago
News Placeholder
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933
Key PointsBethany J. Cavanagh sold 6,198 direct shares for a transaction value of approximately $216,933 at a weighted average price of around $35.00 per share...
Nasdaq News: Markets·11d ago
News Placeholder
Privium Fund Management B.V. Acquires Shares of 61,000 Beam Therapeutics Inc. $BEAM
Privium Fund Management B.V. purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The...
MarketBeat·11d ago
News Placeholder
Wall Street Zen Upgrades Beam Therapeutics (NASDAQ:BEAM) to Hold
Wall Street Zen upgraded Beam Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·12d ago
News Placeholder
Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today
Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits.
Stocktwits·14d ago
News Placeholder
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seventeen analysts that are currently covering the stock...
MarketBeat·14d ago
News Placeholder
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic diseases, enhancing crops, and engineering super-strong fibers.
24-7 Market News·14d ago
<
1
2
...
>

Latest BEAM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.